Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EPS (Basic) (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed EPS (Basic) for 10 consecutive years, with -$0.14 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EPS (Basic) rose 36.36% year-over-year to -$0.14, compared with a TTM value of -$0.0 through Dec 2025, up 99.94%, and an annual FY2025 reading of -$0.62, up 33.33% over the prior year.
  • EPS (Basic) was -$0.14 for Q2 2025 at VYNE Therapeutics, up from -$0.2 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.94 in Q4 2023 and bottomed at -$14.24 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$1.46, with a median of -$0.34 recorded in 2024.
  • The sharpest move saw EPS (Basic) crashed 25400.0% in 2022, then soared 278.85% in 2023.
  • Year by year, EPS (Basic) stood at -$14.24 in 2021, then surged by 107.3% to $1.04 in 2022, then skyrocketed by 278.85% to $3.94 in 2023, then plummeted by 107.11% to -$0.28 in 2024, then soared by 50.0% to -$0.14 in 2025.
  • Business Quant data shows EPS (Basic) for VYNE at -$0.14 in Q2 2025, -$0.2 in Q1 2025, and -$0.28 in Q4 2024.